Clinical trial
Descriptive, Post-marketing, Surveillance Safety Study of Menactra Vaccine
NCT00254995 · Sanofi Pasteur, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00254995 |
|---|---|
| Title | Descriptive, Post-marketing, Surveillance Safety Study of Menactra Vaccine |
| Official title | Post-licensure Safety Surveillance Study of Routine Use of Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra ™) |
| Lead sponsor | Sanofi Pasteur, a Sanofi Company, Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Meningitis, Meningococcal Disease |
| Intervention type | Biological |
| Interventions | None administered in this study |
| Enrollment | 62,626 |
| Start date | Jul 1, 2005 |
| Primary completion | May 1, 2013 |
| Completion | May 1, 2013 |
| First posted | Nov 17, 2005 |
| Last update posted | Apr 19, 2016 |
| Countries | United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: